All In Biotech

NDA 211988 · Heron Theraps INC

Zynrelef Kit

Bupivacaine, Meloxicam · Periarticular · Nonsteroidal Anti-inflammatory Drug; Amide Local Anesthetic

Breakthrough therapyPriority review

Last checked: Nov 20, 2026Latest source record: Apr 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

May 12, 2021

Approved uses

3

Original approval plus efficacy supplements

Registered trials

2,839

342 Phase 3, 228 recruiting

FAERS reports

213

53 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use ( 5.1 ) ZYNRELEF is contraindicated in the setting of coronary artery bypass graft (CABG) surgery ( 4 , 5.1 ) NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or...

What it is approved for

From the label in effect Apr 20, 2026.

ZYNRELEF is indicated in adults for postsurgical analgesia for up to 72 hours after: soft tissue surgical procedures orthopedic surgical procedures – foot and ankle procedures – other orthopedic surgical procedures (e.g., total joint arthroplasty) in which direct exposure to articular cartilage is avoided [see Warnings and Precautions (5.10) ] ZYNRELEF is indicated in adults for postsurgical analgesia for up to 72 hours after: soft tissue surgical procedures orthopedic surgical procedures – foot and ankle procedures – other orthopedic surgical procedures (e.g., total joint arthroplasty) in which direct exposure to articular cartilage is avoided [see Warnings and Precautions (5.10) ] Limitations of Use Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large 4 or more level spinal, and head and neck procedures ( 1 ). Limitations of Use Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large 4 or more level spinal, and head and neck procedures.

Mechanism: ZYNRELEF is a fixed-dose combination of bupivacaine and meloxicam. Bupivacaine Local anesthetics block the generation and the conduction of nerve impulses presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and...

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • ZYNRELEF KIT · BUPIVACAINE 200MG/7ML (29.25MG/ML); MELOXICAM 6MG/7ML (0.88MG/ML) · SOLUTION, EXTENDED RELEASE, PERIARTICULAR · Prescription
  • ZYNRELEF KIT · BUPIVACAINE 300MG/10.5ML (29.25MG/ML); MELOXICAM 9MG/10.5ML (0.88MG/ML) · SOLUTION, EXTENDED RELEASE, PERIARTICULAR · Discontinued
  • ZYNRELEF KIT · BUPIVACAINE 60MG/2.3ML (29.25MG/ML); MELOXICAM 1.8MG/2.3ML (0.88MG/ML) · SOLUTION, EXTENDED RELEASE, PERIARTICULAR · Discontinued
  • ZYNRELEF KIT · BUPIVACAINE 400MG/14ML (29.25MG/ML); MELOXICAM 12MG/14ML (0.88MG/ML) · SOLUTION, EXTENDED RELEASE, PERIARTICULAR · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bupivacaine" as an intervention, any sponsor and status, largest first.

All 2,839 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • wound dehiscence30
  • suture related complication18
  • procedural nausea17
  • seroma12
  • wound necrosis12
  • skin odour abnormal11
  • blister10
  • pain10
  • product odour abnormal10
  • nausea9
  • no adverse event9
  • drug ineffective8

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20211
202291
202358
202419
202524
202620

Recalls

1 FDA enforcement reports for this application.

  • Aug 2, 2022 · Class III · Terminated

    Defective Delivery System: An incorrect 10 mL (12 mL) Luer (slip) syringe packaged in one lot of Zynrelef 400 mg/12 mg kit

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,896 on PubMed

Sponsor: Heron Theraps INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.